Department of Bromatology, Faculty of Pharmacy with the Division of Laboratory Medicine, Medical University of Białystok, Mickiewicza 2D Street, 15-222 Białystok, Poland.
Molecules. 2024 Oct 10;29(20):4796. doi: 10.3390/molecules29204796.
The use of food supplements (FSs) is becoming an increasingly common trend observed in society. This is related to frequently observed nutritional deficiencies and the inability to provide sufficient amounts of nutrients, including vitamins and minerals, through the diet. The ease of registering FSs sometimes results in low-quality preparations on the market. Therefore, our research aimed to assess the content of one of the most popular trace element components, iron (Fe), in FSs available in Poland. This study covered 109 preparations purchased from stationary pharmacies and online pharmacies. The following criteria were used to characterize FSs in the data analysis: the Fe content declared by the manufacturer, pharmaceutical form, type of Fe salt, manufacturer's country of origin, contents of other trace elements or minerals, presence of additional ingredients, age of the target group, and addition of vitamins B2, B6, B12, and C. The Fe content was quantified using atomic absorption spectrometry after mineralization using microwaves. It was demonstrated that 69.73% of the preparations contained more Fe than the value declared by the manufacturer (and corrected for permissible deviations), 11.00% contained less Fe than declared, and only 19.27% were within the norm. In summary, the FS market requires the improvement of manufacturing processes and increased control, which should translate into patient safety.
食品补充剂（FSs）的使用在社会中变得越来越普遍。这与经常观察到的营养缺乏以及无法通过饮食提供足够量的营养素（包括维生素和矿物质）有关。FSs 注册的便利性有时会导致市场上出现低质量的制剂。因此，我们的研究旨在评估波兰市场上可获得的 FSs 中一种最受欢迎的微量元素成分铁（Fe）的含量。这项研究涵盖了从固定药店和在线药店购买的 109 种制剂。在数据分析中，我们使用以下标准来描述 FSs：制造商声明的 Fe 含量、药物形式、Fe 盐的类型、制造商的原产国、其他微量元素或矿物质的含量、是否存在其他成分、目标人群的年龄以及是否添加维生素 B2、B6、B12 和 C。使用微波进行矿物质化后，使用原子吸收光谱法定量测定 Fe 含量。结果表明，69.73%的制剂中 Fe 的含量高于制造商声明的（并校正了允许的偏差），11.00%的制剂中 Fe 的含量低于声明的，只有 19.27%的制剂在正常范围内。总之，FS 市场需要改进制造工艺并加强控制，这应该转化为患者的安全。
